UC Davis

UC Davis Previously Published Works

Title

Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections.

Permalink

<https://escholarship.org/uc/item/342203zd>

Authors

Itell, Hannah L
Kaur, Amitinder
Deere, Jesse D
et al.

Publication Date

2017-08-01

DOI

10.1016/j.coviro.2017.08.005

Peer reviewed

Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections

Hannah L Itell¹, Amitinder Kaur², Jesse D Deere³, Peter A Barry³ and Sallie R Permar^{1,4}

Human cytomegalovirus (HCMV) is the leading opportunistic viral infection in solid organ transplant patients and is the most common congenitally transmitted pathogen worldwide. Despite the significant burden of disease HCMV causes in immunosuppressed patients and infected newborns, there are no licensed preventative vaccines or effective immunotherapeutic treatments for HCMV, largely due to our incomplete understanding of the immune correlates of protection against HCMV infection and disease. Though CMV species-specificity imposes an additional challenge in defining a suitable animal model for HCMV, nonhuman primate (NHP) CMVs are the most genetically related to HCMV. In this review, we discuss the advantages and applicability of rhesus monkey models for studying HCMV infections and pathogenesis and ultimately informing vaccine development.

Addresses

¹ Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA

² Tulane National Primate Research Center, Tulane University, Covington, LA, USA

³ Center for Comparative Medicine, Department of Pathology and Laboratory Medicine, University of California, Davis, CA, USA

⁴ Department of Pediatrics, Duke University Medical Center, Durham, NC, USA

Corresponding author: Permar, Sallie R (sallie.permar@duke.edu)

Current Opinion in Virology 2017, **25**:126–133

This review comes from a themed issue on **Animal models for viral diseases**

Edited by **Cristian Apetrei** and **James Di Santo**

For a complete overview see the [Issue](#) and the [Editorial](#)

Available online 6th September 2017

<http://dx.doi.org/10.1016/j.coviro.2017.08.005>

1879-6257/© 2017 Elsevier B.V. All rights reserved.

Introduction

Human cytomegalovirus (HCMV) is a ubiquitous herpesvirus that establishes persistent infection in its host. While infection of healthy individuals is generally asymptomatic, primary HCMV infection or viral reactivation in immunosuppressed patients, such as AIDS and transplant patients, can lead to dissemination and life-threatening end-organ diseases [1,2]. Congenital HCMV (cCMV) infection can also cause severe clinical outcomes to the

developing fetus and impacts ~1 in every 150 (0.7%) newborns, making it the most common congenitally transmitted pathogen worldwide [3–5]. In the United States alone, an alarming 40,000 congenital infections occur annually and nearly 7,000 infants develop permanent neurological sequelae including microcephaly, sensorineural hearing loss (SNHL), and cognitive impairment [3–5].

Despite the significant global health impact of cCMV and opportunistic HCMV infections, there are no licensed vaccines or effective immunoprophylactic measures to prevent these infections, as clinically tested vaccine candidates have not been successful enough to move forward toward licensure [6,7]. One major challenge of studying HCMV infections and testing vaccines preclinically is that HCMV, like all β -herpesviruses, does not infect non-human species. Therefore, animal models rely on species-specific CMVs, which vary in their biological relevance to HCMV [8]. In this review, we discuss the suitability and application of the rhesus monkey (*Macaca mulatta*) non-human primate (NHP) model for studying CMV infections and disease and for testing immunotherapeutic and prevention strategies.

NHP CMV genomic and functional relevance to HCMV

Because CMV evolution has paralleled mammalian speciation, primate CMVs are more closely related to each other than to CMVs in small animals, such as rats, mice, and guinea pigs [9,10]. Chimpanzee CMV and rhesus CMV (RhCMV) genomes are most similar to HCMV, though chimpanzees are a less accessible animal model due to their endangered population status [10]. Genomic sequencing and annotating of RhCMV isolates 180.92 and 68.1 revealed that 60% of RhCMV open reading frames are homologous to HCMV proteins — notably those encoding structural, immune evasion, replicative, and regulatory proteins [10,11]. For instance, subunits of the pentameric complex (PC; glycoproteins gH/gL and UL128-131A), which is involved in epithelial and endothelial cell tropism and has been reported as the target for the most potently neutralizing antibodies against HCMV, are conserved in RhCMV [10–12,13^{••}]. As with HCMV, the RhCMV subunits interact as a pentamer and are essential for epithelial cell viral entry [13^{••},14,15]. Vaccination of rhesus monkeys with a vector coexpressing the RhCMV pentamer subunits induced neutralizing

antibodies against RhCMV infection of epithelial cells and fibroblasts, which reduced plasma viral loads and supports a functional similarity between RhCMV and HCMV PCs [13^{••}]. Due to these findings, a similar vector was designed to coexpress the HCMV pentamer subunits, and rhesus monkeys vaccinated with this vector stimulated antibodies that neutralized HCMV infection of human epithelial cells, placental macrophages, and fibroblasts [16[•]]. Interestingly, RhCMV 68.1, which lacks regions homologous to HCMV UL128-131A, has been used as a vector to express simian immunodeficiency virus (SIV) proteins and vaccination with this vector induced unconventional CD8⁺ T cell responses, namely targeting of diverse, highly promiscuous epitopes presented by major histocompatibility complex II molecules [17,18]. Nearly 50% of vaccinated animals were protected after SIV challenge, and unconventional T cell responses only occurred when the RhCMV vector lacked HCMV UL128-131A homologs. Thus, the RhCMV PC bears functional relevance to its HCMV homolog and knockdown of certain regions within the pentamer may be advantageous for vaccine delivery.

Similar to the PC, gB, which is essential for viral entry into all host cell types and is an immunodominant target for neutralizing antibodies, shares 60% identity (75% similarity) between RhCMV and HCMV at the amino acid level [19]. Researchers also found that HCMV monoclonal anti-gB antibodies cross-react and cross-neutralize with RhCMV gB (Rhgb) [20]. Anti-Rhgb antibodies have been shown to develop following primary RhCMV infection in rhesus monkeys and to possess neutralizing capabilities, which recapitulates humoral responses to HCMV [21]. In fact, a study recently isolated an anti-Rhgb monoclonal antibody from a rhesus dam following viral challenge [22[•]]. In light of gB containing numerous neutralizing epitopes and two phase II clinical trials finding that a gB subunit vaccine was partially protective against HCMV acquisition, the genomic and functional similarities between RhCMV and HCMV gB, in addition to the PC, are particularly important for an animal model for CMV infection and vaccine immunity [23,24]. Because of the accessibility of rhesus monkeys and the parallels between RhCMV and HCMV genomes and proteins' functions, we will focus this review on the rhesus monkey/RhCMV model as an NHP model for CMV infections.

RhCMV acquisition and persistence

Like HCMV in humans, RhCMV is largely prevalent among rhesus monkey populations and causes life-long infection [25,26]. Nearly half of rhesus monkey infants in breeding colonies are seropositive for RhCMV by 7 months of age, which is just after maternal antibody wanes, and almost all seroconvert by 1 year of age [27,28]. High frequencies of CMV-specific CD4⁺ and CD8⁺ T

lymphocytes are detected in naturally infected CMV-seropositive macaques, with prolonged virus shedding and impaired CD4⁺ T lymphocytes commonly being observed in the first 2–3 years of infection [28–31]. Immune evasion mechanisms that contribute to infection persistence have been found to be similar between rhesus monkeys and humans. Specifically, induction of the cellular interleukin-10 signaling pathway and avoidance of natural killer cell activation, via preventing NKG2D ligand surface expression, contributes to RhCMV and HCMV viral persistence [32–35].

Despite the ubiquitous and persistent nature of RhCMV, efforts using early weaning of young infants to develop specific pathogen-free rhesus monkey colonies were successful in generating RhCMV-seronegative rhesus monkey colonies, which can be used to characterize primary RhCMV acquisition following direct inoculation and to evaluate prophylactic strategies [36]. For instance, prime/boost immunizations containing either Rhgb or a combination of Rhgb, phosphoprotein 65 (pp65), and immediate-early 1 (IE1) proteins have been tested in RhCMV-naïve, healthy adult rhesus monkeys for their effect on RhCMV acquisition and virus shedding using subcutaneous inoculation with epithelial cell-tropic RhCMV UCD52 [37]. In the mock-immunized controls, challenge virus was detectable in plasma, saliva, and urine within 4 weeks of challenge and high levels of virus persisted in the saliva and urine throughout 21 weeks of observation. This study's immunizations were partially effective, with the combined Rhgb/pp65/IE1 vaccine leading to reduced oral shedding in half of the vaccinees. Similar studies have also employed subcutaneous and/or intravenous (IV) inoculation of RhCMV-seronegative monkeys to characterize primary RhCMV infection and to assess prevention strategies, including prime/boost immunizations with the RhCMV PC or with Rhgb/pp65/IE1, which both partially reduced RhCMV plasma viral loads [13^{••},26,38]. Thus, direct inoculation of RhCMV in naïve rhesus monkeys via subcutaneous or IV routes causes quantifiable, persistent infection, which allows assessment of the efficacy of prophylactic strategies. Oral RhCMV challenge and natural vertical transmission models via co-housing with RhCMV-seronegative monkeys are also being trialed as more physiologically relevant challenge models that can better recapitulate human CMV transmission [39].

CMV infection in immune compromised populations

RhCMV-SIV coinfection

Like humans, adult macaques usually manifest with overt CMV disease only under immunosuppressive conditions that result in reactivation of latent RhCMV infection [40–44]. The SIV-rhesus macaque model is the leading animal model of AIDS and recapitulates many features

of untreated HIV infection including the occurrence of RhCMV disease in 30–50% of macaques with simian AIDS [45,46[•]]. Both primary and reactivated RhCMV diseases are associated with rapid progression of simian AIDS and loss of RhCMV-specific humoral and cellular immunity [46[•],47]. The profile of simian AIDS-related RhCMV disease is very similar to HIV-HCMV coinfection, with a few notable exceptions. Unlike in HIV-HCMV coinfection, RhCMV retinitis was not observed during SIV-RhCMV coinfection, and progressive, fatal disease with high RhCMV and SIV loads occurred prior to the onset of severe CD4⁺ T lymphocytopenia [31,46[•]]. In a longitudinal study of SIV-RhCMV coinfecting rhesus macaques, intermittent RhCMV reactivation frequently occurred following impairment of RhCMV-specific CD4⁺ or CD8⁺ T cell immunity, but overt RhCMV disease only occurred after decline of both RhCMV-specific T cells and neutralizing antibodies [46[•]]. A direct relationship between loss of cellular immunity and RhCMV reactivation in NHPs was also observed following *in vivo* administration of CD20⁺ and CD8⁺ lymphocyte-depleting antibodies to SIV-negative pig-tailed macaques and African green monkeys, which experienced a transient increase in RhCMV viremia, while lymphocyte-depleted and SIV-infected pig-tailed macaques developed an irreversible increase in RhCMV viremia and AIDS progression [48]. Overall, SIV-RhCMV coinfection bears many similarities to HIV-HCMV and, like with HCMV, adaptive immunity is critical for immune control of RhCMV infection.

Transplantation-related studies

High CMV seroprevalence rates in rhesus and cynomolgus macaque colonies ensure that most NHP animals used in transplantation-related studies, whether donor or recipient, will be infected with CMV endemic in the host species [49–51]. While there has not been a systematic review of CMV reactivation in immunosuppressed NHPs, accumulating anecdotal reports indicate that CMV reactivation is a frequent cause of morbidity and mortality in transplant-associated studies. As persistent CMV infection is asymptomatic in healthy immune competent animals, CMV sequelae following immune suppression in NHPs have direct relevance for a better understanding, prevention, and treatment of HCMV reactivation, disease, and organ rejection in humans.

Like HCMV infection in humans, detectable RhCMV is cleared from plasma after resolution of primary infection and detectable RhCMV in plasma is rare during persistence [13^{••},51–53]. Thus, the reappearance of RhCMV DNA in plasma is indicative of viral reactivation, caused by impaired immune control of persistent reservoirs of RhCMV-infected cells. Reactivated CMV infections are common in immunosuppressed NHP studies [44,54–58,59^{••},60,61[•],62–64]. Limited studies also indicate that reactivated CMV infections occur in immunosuppressed

pigtailed macaques [65] and baboons [43,66,67]. Studies to date suggest that the frequency and severity of reactivation are related to the degree of immune suppression and/or the extent of allogeneic exposure. Moreover, there is seemingly contradictory evidence that reactivation can occur despite prophylactic antiviral treatment, and that reactivation can resolve in the absence of antivirals.

There is no consensus prevention or treatment strategy in NHPs for anti-CMV inhibitors, and studies have generally adopted dosing and treatment schedules used in human transplant settings, including the use of ganciclovir (GCV), phosphonoformic acid (PFA; foscarnet), cidofovir (CDV), and valganciclovir (valgan). *In vitro* studies demonstrate that the effective concentrations of GCV [68], PFA [60], and CDV (Barry, unpublished) that inhibit RhCMV replication by 50% (EC50) are comparable to the EC50 values reported for HCMV [69–72]. Valgan is delivered orally to treat HCMV infections, and the L-valine ester in valgan must be cleaved *in vivo* by liver and intestinal cells to release the bioactive GCV form of the drug, a cleavage process that occurs in NHP after oral delivery [73].

The frequencies of CMV reactivation and, most importantly, disease vary between studies, ranging from ~14 to 89% [44,54–57,59^{••},60,61[•],62–66]. While it remains unclear what causes the wide disparity, variables between studies potentially include the type of tissue transplanted, the presence of prophylactic anti-CMV drugs, the stringency of the immune suppression regimen, and the parameters used to assess CMV reactivation and/or disease. Some studies prospectively measure CMV viral loads in blood while others determine viral genome copies in plasma or serum. Likewise, some investigators have used clinical sequelae (e.g. pneumonitis, gastroenteritis) as a measure of CMV reactivation while others have performed retrospective analyses based on pathognomonic histopathology and/or immunohistochemical staining for CMV antigens.

As more NHP transplantation studies are performed, it is likely that CMV reactivation will remain a confounding variable in assessing transplant efficacy until there are more efficacious prevention and treatment strategies, uniform diagnostic modalities, and better understandings of the relationship between modes of immunosuppression, allogeneic stimulation, and CMV reactivation. As NHPs are strong predictors of outcomes in humans, these studies can directly improve human prevention and treatment regimens.

Congenital CMV

Congenital HCMV transmission

Despite HCMV being the most common congenitally transmitted pathogen, major gaps remain in our understanding of HCMV *in utero* transmission and maternal

correlates of protection. While infection may ascend from the maternal genital tract to the fetus, more studies have supported the hematogenous route of cCMV transmission, which considers that infection spreads from maternal uterine blood vessels to the villous core and fetus via the placenta [74–76]. A comprehensive understanding of these infection events would aid in rational maternal HCMV vaccine design to prevent congenital transmission. Additionally, defining maternal immune correlates of protection would inform cCMV vaccine strategies. cCMV transmission occurs in 30–40% of women who acquire primary HCMV infection during pregnancy, whereas only 1–2% of infants born to seropositive mothers are congenitally infected [3]. Though vertical transmission rates during maternal HCMV super-infection remain unclear, maternal immunity appears to have a protective role against cCMV transmission. Among maternal immune factors that contribute to partial protection against cCMV, maternal CD4⁺ T cell frequency and lymphoproliferative response, in addition to high-titer and avidity antibodies, have been correlated with reduced cCMV transmission [12,75,77–81]. Despite the associations gained from human cohorts, a relevant cCMV animal model would enable studies to control immune factors and consequently identify protective correlates and cCMV transmission routes.

Congenital RhCMV transmission and pathogenesis

A comprehensive CMV animal model must accurately recapitulate cCMV infection and sequelae. Although rhesus monkey pregnancy is divided into 55-day trimesters as opposed to 90-day trimesters in humans, placental and fetal development is temporally, with most organ development occurring in the first trimester [82]. Multiple studies employing direct RhCMV fetal inoculation *in utero* found that inoculation led to spontaneous abortions or infected fetuses developed brain and neurologic defects analogous to human cCMV cases, which provides support that congenital RhCMV clinical manifestations mimic those of human cCMV [83–86].

Because nearly all rhesus infants seroconvert by 1 year of age, it has remained inconclusive whether RhCMV can be naturally congenitally transmitted. Nevertheless, a study demonstrated that systemic RhCMV inoculation of seronegative pregnant dams resulted in congenital RhCMV transmission and fetal infection [87^{**}]. Dams were challenged during the second trimester with a swarm of high-titer RhCMV variants, which reflects the setting of cCMV infection in humans. All immunosuppressed (CD4⁺ T cell-depleted) animals and 2 of the 3 immunocompetent animals were positive for RhCMV DNA in their amniotic fluid, and placental tissue stained positive for RhCMV-IE1 (Figure 1). These findings establish proof-of-concept RhCMV intrauterine transmission and placental infection. Furthermore, 3 of the

Figure 1

Rhesus monkey placental tissue stained positively for RhCMV-IE1 protein. Placental tissue pictured was from two immunosuppressed seronegative dams. Adapted from Bialas *et al.* [87^{**}].

4 infected immunosuppressed animals had spontaneous abortions and the last surviving infant displayed cCMV-associated sequelae, such as liver lesions and neutropenia. Thus, congenital RhCMV transmission from maternal systemic inoculation, in addition to direct fetal inoculation, recapitulates human cCMV pathogenesis, rendering rhesus monkeys a suitable model for cCMV transmission and disease.

Other work has employed the NHP model for cCMV and demonstrated its applicability. A study compared the humoral responses between two dams that experienced primary infection during pregnancy that either did or did not congenitally transmit RhCMV and found that the nontransmitting dam had an earlier and more robust plasmablast response with more RhCMV-specific antibodies [22^{*}]. Additionally, another study investigated the efficacy of RhCMV hyperimmune globulin (HIG) on preventing RhCMV congenital transmission in immunosuppressed dams and as a treatment for maternal and fetal CMV infection [88^{*}]. In light of conflicting results from small scale studies and phase I/II clinical trials on whether HIG treatment following primary maternal infection is protective and/or therapeutic against cCMV transmission and disease, NHP studies that are assessing the dosage and timing of HIG treatment are particularly relevant [89–93].

Table 1

NHP models for CMV infection		
Model type	Relevance to HCMV	References
Acquisition and persistence	• RhCMV causes persistent infection, associated with induction of IL-10 and inhibition of NK cell activation • Direct inoculation in naïve monkeys mimics primary infection for prevention/challenge studies • Infection induces viral shedding in multiple compartments; poses risk for horizontal transmission	[33] [32] [37] [13**] [16*] [38] [26]
Infection in immune suppressed patients	• SIV-RhCMV coinfection bears many similarities to HIV-HCMV coinfection and progression to AIDS • Type of immune suppression influences risk of CMV reactivation in NHPs • CMV reactivation confounds transplantation outcomes in NHPs	[46*] [62] [59**] [61*] [56]
Fetal infection	• Direct fetal inoculation causes pathogenesis similar to human cCMV • Associated sequelae: microcephaly, limb deformity, central nervous system disease, multiorgan disease	[83] [84*] [85] [86]
Placental transmission	• Maternal inoculation can lead to congenital infection • Intrauterine transmission includes infection of placenta, and leads to fetal loss in the setting of maternal CD4⁺ T cell-depletion • Maternal preexisting antibodies may be protective against transmission	[87**] [22*] [88*]

Conclusion

NHPs offer a considerable advantage in the studies of CMV pathogenesis due to both their similarities to the human host and the genetic and functional homology of the NHP CMV strains and HCMV. The rhesus monkey/RhCMV model is the most characterized of the NHP CMV models and has been utilized for studying the pathogenesis of CMV infection in adult, immunocompromised, pregnant, and fetal monkeys, determining maternal correlates of protection against cCMV, and testing CMV candidate vaccines (NHP models summarized in Table 1). Future studies can employ the NHP models described in this review to inform rational vaccine design and evaluation preclinically, consequently de-risking clinical trials.

Conflict of interest statement

S.R.P., A.K., and P.A.B. provide consulting services to Pfizer Inc. for their preclinical HCMV vaccine program and associated animal models. The other authors declare no conflicts of interest.

References and recommended reading

Papers of particular interest, published within the period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Drew WL: **Cytomegalovirus infection in patients with AIDS**. *Clin Infect Dis* 1992, **14**:608-615.
2. Sia IG, Patel R: **New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients**. *Clin Microbiol Rev* 2000, **13**:83-121 table of contents.

3. Kenneson A, Cannon MJ: **Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection**. *Rev Med Virol* 2007, **17**:253-276.
4. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK: **The "silent" global burden of congenital cytomegalovirus**. *Clin Microbiol Rev* 2013, **26**:86-102.
5. Dollard SC, Grosse SD, Ross DS: **New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection**. *Rev Med Virol* 2007, **17**:355-363.
6. Bialas KM, Permar SR: **The march towards a vaccine for congenital CMV: rationale and models**. *PLoS Pathog* 2016, **12**: e1005355.
7. Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, Mocarski ES, Pass RF, Read JS, Schleiss MR *et al.*: **Priorities for CMV vaccine development**. *Vaccine* 2013, **32**:4-10.
8. Dogra P, Sparer TE: **What we have learned from animal models of HCMV**. *Methods Mol Biol* 2014, **1119**:267-288.
9. McGeoch DJ, Cook S, Dolan A, Jamieson FE, Telford EA: **Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses**. *J Mol Biol* 1995, **247**:443-458.
10. Hansen SG, Strelow LI, Franchi DC, Anders DG, Wong SW: **Complete sequence and genomic analysis of rhesus cytomegalovirus**. *J Virol* 2003, **77**:6620-6636.
11. Rivallier P, Kaur A, Johnson RP, Wang F: **Genomic sequence of rhesus cytomegalovirus 180.92: insights into the coding potential of rhesus cytomegalovirus**. *J Virol* 2006, **80**:4179-4182.
12. Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A, Genini E, Sallusto F, Lanzavecchia A, Corti D, Gerna G: **Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection**. *PLoS ONE* 2013, **8**:e59863.
13. Wussow F, Yue Y, Martinez J, Deere JD, Longmate J, Herrmann A, Barry PA, Diamond DJ: **A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques**. *J Virol* 2013, **87**:1322-1332.

Researchers constructed an MVA vector coexpressing RhCMV pentamer subunit orthologs, and found that the subunits interact as a pentamer, analogous to HCMV. Additionally, RhCMV-seronegative rhesus monkeys

vaccinated with this vector produced neutralizing antibodies that inhibited infection of epithelial cells and fibroblasts and ultimately reduced plasma viral loads, thereby demonstrating the functional similarities between HCMV and RhCMV pentameric complexes and the applicability of the rhesus monkey model for CMV acquisition studies.

14. Lilja AE, Shenk T: **Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types.** *Proc Natl Acad Sci U S A* 2008, **105**:19950-19955.
  15. Yue Y, Kaur A, Lilja A, Diamond DJ, Walter MR, Barry PA: **The susceptibility of primary cultured rhesus macaque kidney epithelial cells to rhesus cytomegalovirus strains.** *J Gen Virol* 2016, **97**:1426-1438.
  16. Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E, Flechsig C, Newell M, Tran E, Ortiz J, La Rosa C *et al.*: **Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex.** *PLoS Pathog* 2014, **10**:e1004524.
- Expanding upon their findings in Wussow *et al.*, 2013, researchers generated another MVA vector that coexpresses the HCMV pentamer subunits, instead of those of RhCMV. They also made similar vectors for gH/gL, UL128-UL131A, and gB. Neutralizing antibodies from rhesus monkeys after vaccination with the MVA-pentamer blocked infection of human epithelial cells, placental macrophages, and fibroblasts, and were more durable and robust than those from rhesus monkeys vaccinated with other MVA combinations. These findings support the applicability of a rhesus monkey model for CMV vaccine design.
17. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T *et al.*: **Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine.** *Nature* 2011, **473**:523-527.
  18. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, Gilbride RM, Lewis MS, Gilliam AN, Ventura AB *et al.*: **Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms.** *Science* 2013, **340**:1237874.
  19. Kravitz RH, Sciabica KS, Cho K, Luciw PA, Barry PA: **Cloning and characterization of rhesus cytomegalovirus glycoprotein B.** *J Gen Virol* 1997, **78**(Pt 8):2009-2013.
  20. Kropff B, Mach M: **Identification of the gene coding for rhesus cytomegalovirus glycoprotein B and immunological analysis of the protein.** *J Gen Virol* 1997, **78**(Pt 8):1999-2007.
  21. Yue Y, Zhou SS, Barry PA: **Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques.** *J Gen Virol* 2003, **84**:3371-3379.
  22. Fan Q, Nelson CS, Bialas KM, Chiuppesi F, Amos J, Gurley TC, Marshall DJ, Eudailey J, Heimsath H, Himes J *et al.*: **Plasmablast response to primary rhesus cytomegalovirus infection in a monkey model of congenital CMV transmission.** *Clin Vaccine Immunol* 2017.
- This study demonstrates how the rhesus monkey model for congenital CMV can be employed to understand maternal immune correlates of protection. Comparison of a RhCMV-transmitting dam to a nontransmitting dam revealed that the nontransmitting dam had an earlier and more robust plasmablast response. Furthermore, this was the first report to identify and isolate RhCMV gB-specific monoclonal antibodies, which suggests a potential to use the rhesus monkey congenital CMV model for antibody-based prophylaxis.
23. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C *et al.*: **Vaccine prevention of maternal cytomegalovirus infection.** *N Engl J Med* 2009, **360**:1191-1199.
  24. Bernstein DI, Munoz FM, Callahan ST, Rupp R, Wootton SH, Edwards KM, Turley CB, Stanberry LR, Patel SM, McNeal MM *et al.*: **Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: a randomized clinical trial.** *Vaccine* 2016, **34**:313-319.
  25. Huff JL, Eberle R, Capitanio J, Zhou SS, Barry PA: **Differential detection of B virus and rhesus cytomegalovirus in rhesus macaques.** *J Gen Virol* 2003, **84**:83-92.
  26. Lockridge KM, Seagar G, Zhou SS, Yue Y, Mandell CP, Barry PA: **Pathogenesis of experimental rhesus cytomegalovirus infection.** *J Virol* 1999, **73**:9576-9583.
  27. Vogel P, Weigler BJ, Kerr H, Hendrickx AG, Barry PA: **Seroepidemiologic studies of cytomegalovirus infection in a breeding population of rhesus macaques.** *Lab Anim Sci* 1994, **44**:25-30.
  28. Kaur A, Daniel MD, Hempel D, Lee-Parritz D, Hirsch MS, Johnson RP: **Cytotoxic T-lymphocyte responses to cytomegalovirus in normal and simian immunodeficiency virus-infected rhesus macaques.** *J Virol* 1996, **70**:7725-7733.
  29. Antoine P, Varner V, Carville A, Connoles M, Marchant A, Kaur A: **Postnatal acquisition of primary rhesus cytomegalovirus infection is associated with prolonged virus shedding and impaired CD4+ T lymphocyte function.** *J Infect Dis* 2014.
  30. Chan KS, Kaur A: **Flow cytometric detection of degranulation reveals phenotypic heterogeneity of degranulating CMV-specific CD8+ T lymphocytes in rhesus macaques.** *J Immunol Methods* 2007, **325**:20-34.
  31. Kaur A, Hale CL, Noren B, Kassiss N, Simon MA, Johnson RP: **Decreased frequency of cytomegalovirus (CMV)-specific CD4+ T lymphocytes in simian immunodeficiency virus-infected rhesus macaques: inverse relationship with CMV viremia.** *J Virol* 2002, **76**:3646-3658.
  32. Sturgill ER, Malouli D, Hansen SG, Burwitz BJ, Seo S, Schneider CL, Womack JL, Verweij MC, Ventura AB, Bhusari A *et al.*: **Natural killer cell evasion is essential for infection by rhesus cytomegalovirus.** *PLoS Pathog* 2016, **12**:e1005868.
  33. Eberhardt MK, Deshpande A, Fike J, Short R, Schmidt KA, Blozis SA, Walter MR, Barry PA: **Exploitation of interleukin-10 (IL-10) signaling pathways: alternate roles of viral and cellular IL-10 in rhesus cytomegalovirus infection.** *J Virol* 2016, **90**:9920-9930.
  34. Slobedman B, Barry PA, Spencer JV, Avdic S, Abendroth A: **Virus-encoded homologs of cellular interleukin-10 and their control of host immune function.** *J Virol* 2009, **83**:9618-9629.
  35. Slavuljica I, Krmpotic A, Jonjic S: **Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response.** *Front Immunol* 2011, **2**:85.
  36. Barry PA, Strelow L: **Development of breeding populations of rhesus macaques (*Macaca mulatta*) that are specific pathogen-free for rhesus cytomegalovirus.** *Comp Med* 2008, **58**:43-46.
  37. Abel K, Martinez J, Yue Y, Lacey SF, Wang Z, Strelow L, Dasgupta A, Li Z, Schmidt KA, Oxford KL *et al.*: **Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.** *J Virol* 2011, **85**:2878-2890.
  38. Yue Y, Wang Z, Abel K, Li J, Strelow L, Mandarino A, Eberhardt MK, Schmidt KA, Diamond DJ, Barry PA: **Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques.** *Med Microbiol Immunol* 2008, **197**:117-123.
  39. dela Pena MG, Strelow L, Barry PA, Abel K: **Use of specific-pathogen-free (SPF) rhesus macaques to better model oral pediatric cytomegalovirus infection.** *J Med Primatol* 2012, **41**:225-229.
  40. Baskin GB: **Disseminated cytomegalovirus infection in immunodeficient rhesus monkeys.** *Am J Pathol* 1987, **129**:345-352.
  41. Swack NS, Hsiung GD: **Natural and experimental simian cytomegalovirus infections at a primate center.** *J Med Primatol* 1982, **11**:169-177.
  42. Ohtaki S, Kodama H, Hondo R, Kurata T: **Activation of cytomegalovirus infection in immunosuppressed cynomolgus monkeys inoculated with varicella-zoster virus.** *Acta Pathol Jpn* 1986, **36**:1537-1552.
  43. Mueller NJ, Barth RN, Yamamoto S, Kitamura H, Patience C, Yamada K, Cooper DK, Sachs DH, Kaur A, Fishman JA: **Activation of cytomegalovirus in pig-to-primate organ xenotransplantation.** *J Virol* 2002, **76**:4734-4740.
  44. Pearson TC, Trambley J, Odom K, Anderson DC, Cowan S, Bray R, Lin A, Hollenbaugh D, Aruffo A, Siadak AW *et al.*: **Anti-CD40 therapy extends renal allograft survival in rhesus macaques.** *Transplantation* 2002, **74**:933-940.

45. Baskin GB, Murphey-Corb M, Watson EA, Martin LN: **Necropsy findings in rhesus monkeys experimentally infected with cultured simian immunodeficiency virus (SIV)/delta.** *Vet Pathol* 1988, **25**:456-467.
  46. Kaur A, Kassis N, Hale CL, Simon M, Elliott M, Gomez-Yafal A, Lifson JD, Desrosiers RC, Wang F, Barry P *et al.*: **Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS.** *J Virol* 2003, **77**:5749-5758.
- This study prospectively assessed 11 rhesus monkeys with SIV-RhCMV coinfection, 6 of which had CMV reactivation-associated disease at death. The researchers found that the monkeys with CMV disease had significantly higher levels of plasma SIV RNA and CMV DNA and lower titers of binding and neutralizing anti-CMV antibodies at time of death, and that they experienced a significant decline of CMV-specific CD4⁺ and CD8⁺ lymphocytes over time. These results suggest that CMV disease caused by viral reactivation in the setting of AIDS is associated with a decline in both humoral and cellular CMV-specific immune responses.
47. Sequer G, Britt WJ, Lakeman FD, Lockridge KM, Tarara RP, Canfield DR, Zhou SS, Gardner MB, Barry PA: **Experimental coinfection of rhesus macaques with rhesus cytomegalovirus and simian immunodeficiency virus: pathogenesis.** *J Virol* 2002, **76**:7661-7671.
  48. Schmitz JE, Zahn RC, Brown CR, Rett MD, Li M, Tang H, Pryputniewicz S, Byrum RA, Kaur A, Montefiori DC *et al.*: **Inhibition of adaptive immune responses leads to a fatal clinical outcome in SIV-infected pigtailed macaques but not vervet African green monkeys.** *PLoS Pathog* 2009, **5**:e1000691.
  49. Ambagala AP, Marsh A, Chan J, Pilon R, Fournier J, Mazzulli T, Sandstrom P, Willer DO, MacDonald KS: **Isolation and characterization of cynomolgus macaque (*Macaca fascicularis*) cytomegalovirus (CyCMV).** *Virology* 2011, **412**:125-135.
  50. Marsh AK, Willer DO, Ambagala AP, Dzamba M, Chan JK, Pilon R, Fournier J, Sandstrom P, Brudno M, Macdonald KS: **Genomic sequencing and characterization of cynomolgus macaque cytomegalovirus.** *J Virol* 2011.
  51. Früh K, Malouli D, Oxford K, Barry P: **Non-human-primate models of cytomegalovirus infection, prevention, and therapy.** In *Cytomegaloviruses: From Molecular Pathogenesis to Therapy*, vol II. Edited by Reddehase M. Horizon: Caister Academic Press; 2013.
  52. Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF: **Asymptomatic primary cytomegalovirus infection: virologic and immunologic features.** *J Infect Dis* 1999, **180**:702-707.
  53. Oxford KL, Strelow L, Yue Y, Chang WL, Schmidt KA, Diamond DJ, Barry PA: **Open reading frames carried on UL/b' are implicated in shedding and horizontal transmission of rhesus cytomegalovirus in rhesus monkeys.** *J Virol* 2011, **85**:5105-5114.
  54. Anderson DJ, Lo DJ, Leopardi F, Song M, Turgeon NA, Strobert EA, Jenkins JB, Wang R, Reimann KA, Larsen CP *et al.*: **Anti-leukocyte function-associated antigen 1 therapy in a nonhuman primate renal transplant model of costimulation blockade-resistant rejection.** *Am J Transplant* 2016, **16**:1456-1464.
  55. Hausteil SV, Kolterman AJ, Sundblad JJ, Fechner JH, Knechtle SJ: **Nonhuman primate infections after organ transplantation.** *ILAR J* 2008, **49**:209-219.
  56. Kean LS, Adams AB, Strobert E, Hendrix R, Gangappa S, Jones TR, Shirasugi N, Rigby MR, Hamby K, Jiang J *et al.*: **Induction of chimerism in rhesus macaques through stem cell transplant and costimulation blockade-based immunosuppression.** *Am J Transplant* 2007, **7**:320-335.
  57. Lowe MC, Badell IR, Turner AP, Thompson PW, Leopardi FV, Strobert EA, Larsen CP, Kirk AD: **Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy.** *Am J Transplant* 2013, **13**:312-319.
  58. Wils EJ, Aerts-Kaya FS, Rombouts EJ, van Mourik I, Rijken-Schelen A, Visser TP, Braakman E, Wagemaker G, Cornelissen JJ: **Keratinocyte growth factor and stem cell factor to improve**

thymopoiesis after autologous CD34⁺ cell transplantation in rhesus macaques. *Biol Blood Marrow Transplant* 2012, **18**:55-65.

59. Zheng HB, Watkins B, Tkachev V, Yu S, Tran D, Furlan S, Zeleski K, Singh K, Hamby K, Hotchkiss C *et al.*: **The knife's edge of tolerance: inducing stable multilineage mixed chimerism but with a significant risk of CMV reactivation and disease in rhesus macaques.** *Am J Transplant* 2017, **17**:657-670.

To improve tolerance during NHP transplants, the researchers employed an adapted regimen to MHC-matched rhesus monkeys that resulted in prolonged multilineage hematopoietic chimerism and, in the setting of T cell chimerism, improved donor-specific skin graft acceptance. However, the transplant strategy was also associated with a significant risk of RhCMV reactivation and disease, caused by the setting of suppressed CMV-specific T cell immunity. This study thus reports an improved regimen that induced prolonged tolerance and also emphasizes the challenge of CMV reactivation in the setting of NHP transplants, similar to human transplants.

60. Cavicchioli L, Zanetti R, Ferraresso S, Crossan C, Barry PA, Boldrin M, Vadori M, Ferro S, Calabrese F, Scobie L *et al.*: **Expression of recipient cytomegalovirus in immunosuppressed and xenotransplanted *Macaca fascicularis* may be related to more severe gastrointestinal lesions.** *Xenotransplantation* 2015, **22**:135-143.
61. Duran-Struuck R, Sondermeijer HP, Buhler L, Alonso-Guallart P, Zitsman J, Kato Y, Wu A, McMurphy AN, Woodland D, Griesemer A *et al.*: **Effect of ex vivo-expanded recipient regulatory T cells on hematopoietic chimerism and kidney allograft tolerance across MHC Barriers in cynomolgus macaques.** *Transplantation* 2017, **101**:274-283.

Based on a transplant strategy that has been successful in mice, cynomolgus macaques were conditioned, infused with or without recipient regulatory T (Treg) cells, and received MHC-mismatched bone marrow transplants. Though monkeys without Treg infusion achieved transient mixed chimerism, some of the Treg infused animals induced prolonged chimerism in all lineages, including T cells, which supports the use of recipient Treg infusion for immune tolerance. Interestingly, early CMV reactivation was associated with early failure of induced chimerism, regardless of Treg infusion, emphasizing the importance of determining a strategy to control CMV reactivation during states of immune tolerance.

62. Han D, Berman DM, Willman M, Buchwald P, Rothen D, Kenyon NM, Kenyon NS: **Choice of immunosuppression influences cytomegalovirus DNAemia in cynomolgus monkey (*Macaca fascicularis*) islet allograft recipients.** *Cell Transplant* 2010, **19**:1547-1561.
63. Jonker M, Ringers J, Kuhn EM, Hart B, Foulkes R: **Treatment with anti-MHC-class-II antibody postpones kidney allograft rejection in primates but increases the risk of CMV activation.** *Am J Transplant* 2004, **4**:1756-1761.
64. Oura T, Hotta K, Lei J, Markmann J, Rosales I, Dehnadi A, Kawai K, Ndishabandi D, Smith RN, Cosimi AB *et al.*: **Immunosuppression with CD40 costimulatory blockade plus rapamycin for simultaneous islet-kidney transplantation in nonhuman primates.** *Am J Transplant* 2017, **17**:646-656.
65. Bielefeldt-Ohmann H, Gough M, Durning M, Kelley S, Liggitt HD, Kiem HP: **Greater sensitivity of pigtailed macaques (*Macaca nemestrina*) than baboons to total body irradiation.** *J Comp Pathol* 2004, **131**:77-86.
66. Kawauchi M, Gundry SR, de Begona JA, Razzouk AJ, Bouchart F, Fukushima N, Hauck AJ, Weeks DA, Nehlsen-Cannarella S, Bailey LL: **Prolonged survival of orthotopically transplanted heart xenograft in infant baboons.** *J Thorac Cardiovasc Surg* 1993, **106**:779-786.
67. Mueller NJ, Sullings K, Gollackner B, Yamamoto S, Knosalla C, Wilkinson RA, Kaur A, Sachs DH, Yamada K, Cooper DK *et al.*: **Reduced efficacy of ganciclovir against porcine and baboon cytomegalovirus in pig-to-baboon xenotransplantation.** *Am J Transplant* 2003, **3**:1057-1064.
68. Swanson R, Bergquam E, Wong SW: **Characterization of rhesus cytomegalovirus genes associated with anti-viral susceptibility.** *Virology* 1998, **240**:338-348.
69. Williams-Aziz SL, Hartline CB, Harden EA, Daily SL, Prichard MN, Kushner NL, Beadle JR, Wan WB, Hostetler KY, Kern ER: **Comparative activities of lipid esters of cidofovir and cyclic**

- cidofovir against replication of herpesviruses in vitro.** *Antimicrob Agents Chemother* 2005, **49**:3724-3733.
70. Sullivan V, Biron KK, Talarico CL, Stanat SC, Davis M, Pozzi LM, Coen DM: **A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives.** *Antimicrob Agents Chemother* 1993, **37**:19-25.
  71. Biron KK, Fyfe JA, Stanat SC, Leslie LK, Sorrell JB, Lambe CU, Coen DM: **A human cytomegalovirus mutant resistant to the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine (BW B759U) induces reduced levels of BW B759U triphosphate.** *Proc Natl Acad Sci U S A* 1986, **83**:8769-8773.
  72. Lurain NS, Thompson KD, Holmes EW, Read GS: **Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents.** *J Virol* 1992, **66**:7146-7152.
  73. Menzel O, Birraux J, Wildhaber BE, Jond C, Lasne F, Habre W, Trono D, Nguyen TH, Chardot C: **Biosafety in ex vivo gene therapy and conditional ablation of lentivirally transduced hepatocytes in nonhuman primates.** *Mol Ther* 2009, **17**:1754-1760.
  74. Coonrod D, Collier AC, Ashley R, DeRouen T, Corey L: **Association between cytomegalovirus seroconversion and upper genital tract infection among women attending a sexually transmitted disease clinic: a prospective study.** *J Infect Dis* 1998, **177**:1188-1193.
  75. Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L: **Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis.** *Am J Pathol* 2006, **168**:1210-1226.
  76. Pereira L, Maidji E, McDonagh S, Tabata T: **Insights into viral transmission at the uterine-placental interface.** *Trends Microbiol* 2005, **13**:164-174.
  77. Fujikawa T, Numazaki K, Asanuma H, Kudo R, Tsutsumi H: **Frequency of human cytomegalovirus-specific T cells during pregnancy determined by intracellular cytokine staining.** *J Med Virol* 2003, **71**:527-531.
  78. Lilleri D, Fornara C, Furione M, Zavattoni M, Revello MG, Gerna G: **Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus.** *J Infect Dis* 2007, **195**:1062-1070.
  79. Revello MG, Lilleri D, Zavattoni M, Furione M, Genini E, Comolli G, Gerna G: **Lymphoproliferative response in primary human cytomegalovirus (HCMV) infection is delayed in HCMV transmitter mothers.** *J Infect Dis* 2006, **193**:269-276.
  80. Zydek M, Pettitt M, Fang-Hoover J, Adler B, Kauvar LM, Pereira L, Tabata T: **HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex.** *Viruses* 2014, **6**:1346-1364.
  81. Itell HL, Nelson CS, Martinez DR, Permar SR: **Maternal immune correlates of protection against placental transmission of cytomegalovirus.** *Placenta* 2017.
  82. Tanimura T, Tanioka Y: **Comparison of embryonic and foetal development in man and rhesus monkey.** *Lab Anim Hndbk* 1975:205-233.
  83. Tarantal AF, Salamat MS, Britt WJ, Luciw PA, Hendrickx AG, Barry PA: **Neuropathogenesis induced by rhesus cytomegalovirus in fetal rhesus monkeys (*Macaca mulatta*).** *J Infect Dis* 1998, **177**:446-450.
  84. Barry PA, Lockridge KM, Salamat S, Tinling SP, Yue Y, Zhou SS, Gospe SM Jr, Britt WJ, Tarantal AF: **Nonhuman primate models of intrauterine cytomegalovirus infection.** *ILAR J* 2006, **47**:49-64.
  85. Chang WL, Tarantal AF, Zhou SS, Borowsky AD, Barry PA: **A recombinant rhesus cytomegalovirus expressing enhanced green fluorescent protein retains the wild-type phenotype and pathogenicity in fetal macaques.** *J Virol* 2002, **76**:9493-9504.
  86. Andrews EJ: **Spontaneous abortions in *Macaca mulatta*.** *Lab Anim Sci* 1971, **21**:964.
  87. Bialas KM, Tanaka T, Tran D, Varner V, Cisneros De La Rosa E, Chiuppesi F, Wussow F, Kattenhorn L, Macri S, Kunz EL *et al.*: **Maternal CD4+ T cells protect against severe congenital cytomegalovirus disease in a novel nonhuman primate model of placental cytomegalovirus transmission.** *Proc Natl Acad Sci USA* 2015, **112**:13645-13650.
- This report details the first cases of congenitally transmitted RhCMV following RhCMV systemic inoculation of immunocompetent and CD4⁺ T cell-depleted RhCMV-seronegative pregnant dams, thus establishing proof-of-concept congenital RhCMV transmission and placental infection. Additionally, infected fetuses of CD4⁺ T cell-depleted dams either spontaneously aborted or developed cCMV-associated sequelae after birth, which highlights the role of CD4⁺ T cell in cCMV outcome and disease similarities between congenital HCMV and RhCMV.
88. Nelson CS, Cruz DV, Tran D, Bialas KM, Stamper L, Wu H, Gilbert M, Blair R, Alvarez X, Itell H *et al.*: **Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys.** *JCI Insight* 2017:2.
- Researchers employed the rhesus monkey model for placental CMV transmission to assess whether preexisting maternal antibodies can protect against congenital RhCMV infection during primary maternal infection. Pregnant, RhCMV-seronegative dams were CD4⁺ T cell-depleted and treated with either standardly produced or high neutralizing potency antibody preparations, prior to being intravenously challenged with RhCMV. Antibody preinfusion universally protected against fetal loss in all treatment groups, and animals that received the dose-optimized, potentially neutralizing antibody regimen additionally had decreased systemic viral replication and did not transmit RhCMV to their developing infant. These results suggest that preexisting, potentially neutralizing antibodies can protect against both fetal loss and placental RhCMV transmission and therefore future cCMV vaccine candidates could focus solely on eliciting potent antibody immunity.
89. La Torre R, Nigro G, Mazzocco M, Best AM, Adler SP: **Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease.** *Clin Infect Dis* 2006, **43**:994-1000.
  90. Nigro G, Adler SP, La Torre R, Best AM: **Passive immunization during pregnancy for congenital cytomegalovirus infection.** *N Engl J Med* 2005, **353**:1350-1362.
  91. Nigro G, Adler SP, Parruti G, Anceschi MM, Coclite E, Pezone I, Di Renzo GC: **Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy—a case-control study of the outcome in children.** *J Infect Dis* 2012, **205**:215-227.
  92. Visentin S, Manara R, Milanese L, Da Roit A, Forner G, Salviato E, Citton V, Magno FM, Orzan E, Morando C *et al.*: **Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age.** *Clin Infect Dis* 2012, **55**:497-503.
  93. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, Guaschino S, Vergani P, Todros T, Frusca T *et al.*: **A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus.** *N Engl J Med* 2014, **370**:1316-1326.